Interestingly, P-DXd shows in vitro and in vivo efficacy, even in the presence of Aspn+ cancer-associated stromal cells, suggesting that P-DXd may have a higher affinity to HER3 than ASPN or the P-DXd binding epitope is not obstructed by ASPN binding. Here, ERBB3 is linked to cancer.